COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Jaguar Health, Inc. extends maturity date of convertible promissory notes in bridge financing. CEO Lisa Conte appreciates investors' support for core programs -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding
